Genentech to Start Second Phase 3 Trial of Crenezumab as Alzheimer’s Treatment

Genentech to Start Second Phase 3 Trial of Crenezumab as Alzheimer’s Treatment
Genentech will start a second Phase 3 clinical trial of crenezumab, an anti-Amyloid-beta antibody for treating Alzheimer's disease that was developed by its partner, AC Immune. This trial, CREAD2, will complement the current randomized, double-blind, placebo-controlled, parallel group Phase 3 clinical trial (CREAD1, NCT02670083). CREAD1 is evaluating the effectiveness and safety of crenezumab versus a placebo in 750 participants with early to mild AD.  Participants are being randomly assigned to receive an intravenous dose of crenezumab or a placebo every four weeks for 100 weeks. The study's final effectiveness and safety assessment will occur 52 weeks after the last crenezumab dose. CREAD1 is expected to run until 2020. Investigators will evaluate any changes in participants' dementia rating and their performance on neuropsychological tests. More details about the CREAD2 trial design, which will include the same number of participants, will be announced soon. "We are delighted with the strong commitment of our partner Genentech to developing crenezumab as a potential disease-modifying therapy for Alzheimer's," Professor Andrea Pfeifer, CEO of AC Immune, said in a press release. "Given the recent disappointing results of other therapies, all of us in the Alzheimer's community need to redouble our efforts to combat one of society's biggest challenges. We remain
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *